| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-01-29 |
| タイトル |
|
|
タイトル |
MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
microRNA |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Extracellular vesicles (EVs) |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Mac-2-binding protein glycosylation isomer (M2BPGi) |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Regression of liver fibrosis |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
鈴木, 孝典
松浦, 健太郎
Nagura, Yoshihito
Ito, Kyoko
Ogawa, Shintaro
河村, 逸外
藤原, 圭
Nagaoka, Katsuya
Iio, Etsuko
Watanabe, Takehisa
片岡, 洋望
Tanaka, Yasuhito
|
| 抄録(英) |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: We retrospectively investigated microRNA (miRNA) levels in serum-derived extracellular vesicles (EVs) as predictive indicators for regression of liver fibrosis, after achievement of a sustained virological response (SVR) by direct-acting antiviral (DAA) therapy for chronic hepatitis C (CHC).
Methods: The study subjects were recruited from a historical cohort of 108 CHC patients whose pretreatment serum Mac-2-binding protein glycosylation isomer (M2BPGi) levels were ≥ 2.0 cut-off index (COI). We classified patients with M2BPGi levels < 1.76 and ≥ 1.76 COI at 2 years after the end of treatment (EOT) into the regression and non-regression groups, respectively. Eleven of the patients were assigned to the discovery set, and we comprehensively investigated the miRNAs contained in serum-derived EVs at 24 weeks after the EOT (EOT24W), using RNA sequencing. The remaining 97 patients were assigned to the validation set, and reproducibility was verified by quantitative real-time PCR.
Results: Through analysis of the discovery and validation sets, we identified miR-223-3p and miR-1290 as candidate predictors. Subsequently, we analyzed various clinical data, including these candidate miRNAs. Multivariate analyses revealed that the levels of miR-223-3p at EOT24W were significantly associated with regression of M2BPGi-based liver fibrosis (Odds ratio: 1.380; P = 0.024). Consistent results were obtained, even when the serum M2BPGi levels were aligned by propensity score matching and in patients with advanced M2BPGi-based liver fibrosis (pretreatment M2BPGi levels ≥ 3.3 COI).
Conclusions: The miR-223-3p level in serum-derived EVs at EOT24W is a feasible predictor of regression of M2BPGi-based liver fibrosis after achievement of an SVR by DAA therapy. |
|
言語 |
en |
| 書誌情報 |
en : Journal of Gastroenterology
巻 59,
号 8,
p. 719-731,
発行日 2024-05-13
|
| 出版者 |
|
|
出版者 |
Springer Nature |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
09441174 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
14355922 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s00535-024-02115-w |
| 権利 |
|
|
権利情報 |
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s00535-024-02115-w |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
J11-JG-09441174-59-719-suz.pdf (1.6 MB)
